Rhythm Biosciences (FRA:0RY) YoY EBITDA Growth: 33.33% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:0RY Rhythm Biosciences Ltd FRA:0RY
18 GF Score
Price €0.05
! 1 Warning Sign
View Full Analysis

What is Rhythm Biosciences YoY EBITDA Growth?

Rhythm Biosciences FRA:0RY -3.00% 18 YoY EBITDA Growth is 33.33% as of Jun. 2026. GuruFocus rates FRA:0RY with a GF Score™ of 18/100. The stock has 1 warning sign investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Rhythm Biosciences's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 33.33%.

Rhythm Biosciences's EBITDA per Share for the six months ended in Jun. 2026 was €-0.01.

Rhythm Biosciences YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Rhythm Biosciences's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhythm Biosciences YoY EBITDA Growth Chart

Rhythm Biosciences Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only -59.09 8.57 43.75 61.11 -42.86

Rhythm Biosciences Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.43 128.57 18.18 -300.00 33.33
FRA:0RY
18GF Score
Rhythm Biosciences Ltd FRA:0RY
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rhythm Biosciences YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Rhythm Biosciences's YoY EBITDA Growth for the fiscal year that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (A: Jun. 2026 )
=(EBITDA per Share (A: Jun. 2026 )-EBITDA per Share (A: Jun. 2025 ))/ | EBITDA per Share (A: Jun. 2025 ) |
=(-0.01--0.007)/ | -0.007 |
=-42.86 %

Rhythm Biosciences's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-0.006--0.009)/ | -0.009 |
=33.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 33.33% mean?
Rhythm Biosciences (FRA:0RY) has a YoY EBITDA Growth of 33.33% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Rhythm Biosciences and its competitors.
Is Rhythm Biosciences' YoY EBITDA Growth too high?
Rhythm Biosciences' current YoY EBITDA Growth is 33.33%. Overall, Rhythm Biosciences has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Rhythm Biosciences' YoY EBITDA Growth compare to TMO and DHR?
Rhythm Biosciences' YoY EBITDA Growth of 33.33% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Diagnostics & Research company?
A good YoY EBITDA Growth depends on the Medical Diagnostics & Research industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Rhythm Biosciences and its competitors. Rhythm Biosciences's current YoY EBITDA Growth is 33.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Biosciences stock overvalued right now?
Rhythm Biosciences (FRA:0RY) has a current YoY EBITDA Growth of 33.33%. The current YoY EBITDA Growth is 33.33%. Rhythm Biosciences' overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Rhythm Biosciences (FRA:0RY), the current YoY EBITDA Growth is 33.33% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rhythm Biosciences Business Description

Other Exchanges RHY:Australia
Address 30 Flemington Road, Bio21 Institute, Parkville, Melbourne, VIC, AUS, 3010
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. The product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. The company operates predominantly in one business and geographical segment which is the research and development of biosciences in Australia.
18GF Score

Get the complete analysis for FRA:0RY

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.05
Price